LIFECORE REPORTS RESULTS OF ETHICON CLINICAL TRIAL
LIFECORE REPORTS RESULTS OF ETHICON CLINICAL TRIAL CHASKA, Minn., Oct. 5 /PRNewswire/ -- Lifecore Biomedical, Inc.
(NASDAQ: LCBM) announced today that it had been informed by an official of the Ethicon, Inc., division of the Johnson and Johnson Company after the market close late Friday, Oct. 2, that partial statistical analysis of data resulting from Ethicon's ongoing anti-adhesion clinical trial with Lifecore's Tenalure(R) Brand sodium hyaluronate product was not demonstrating anticipated levels of efficacy.
Lifecore indicated that the two companies were continuing to confer regarding the future direction of the ongoing clinical evaluation. Several options are available to the companies including further evaluation of the current hyaluronate product, bringing a second generation hyaluronate product to the clinic, or, discontinuing the project. Lifecore's President and CEO James W. Bracke, indicated that he was optimistic that the companies could continue to collaborate on this clinical project although the time frame for the project was "likely to be extended." Lifecore develops, manufactures and markets sterile medical devices for a variety of surgical applications, through both direct sales and OEM supplier relationships. -0- 10/5/92 /CONTACT: James W. Bracke or John C. Heinmiller, 612-368-4300, both of Lifecore Biomedical/ (LCBM) CO: Lifecore Biomedical, Inc. ST: Minnesota IN: MTC SU:
AL -- MN006 -- 6483 10/05/92 10:19 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 5, 1992|
|Previous Article:||SHAWMUT NATIONAL CORPORATION INTRODUCES BILL-LINE A TELEPHONE-BASED BILL-PAYING SERVICE|
|Next Article:||CHECK PROCESSING LEAPS TO THE 21ST CENTURY: IBM TO DELIVER HPTS PROOF-OF-DEPOSIT IN DECEMBER|